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Abstract 
This review provides an update for the international research community on the cell modeling tools 
that could accelerate the understanding of SARS-CoV-2 infection mechanisms and could thus speed 
up the development of vaccines and therapeutic agents against COVID-19. 
Many bioengineering groups are actively developing frontier tools that are capable of providing 
realistic three-dimensional (3D) models for biological research, including cell culture scaffolds, 
microfluidic chambers for the culture of tissue equivalents and organoids, and implantable windows 
for intravital imaging. 
Here, we review the most innovative study models based on these bioengineering tools in the 
context of virology and vaccinology. To make it easier for scientists working on SARS-CoV-2 to 
identify and apply specific tools, we discuss how they could accelerate the discovery and preclinical 
development of antiviral drugs and vaccines, compared to conventional models. 
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Introduction 
As of May 8, 2020, the 2019 novel coronavirus 
SARS-CoV-2 was responsible in 215 countries for 
3,767,744 infections and 259,593 deaths from the 
related disease, defined as COronaVIrus Disease 2019 
(COVID-19) [1]. The human population has no 
immunity to SARS-CoV-2 because this virus had 
never previously infected humans before its initial 
outbreak in December 2019. Until now, no drugs or 
biologics have been proven to be effective for the 
prevention or treatment of COVID-19. To deal with 
this pandemic, apart from non-pharmaceutical 
containment measures including quarantine and 
maintenance of social distance, possible interventions 
consist of the repurposing of existing pharmaceutical 
products, along with the development of new 
products and vaccines [2-4]. 
The development of a radically new 
pharmaceutical product, either traditional, or 
biological such as an antibody targeting a 
SARS-CoV-2 receptor, is subject to regulatory 
approval for use in humans based on three steps: 1) 
lab discovery in vitro on cell cultures; 2) preclinical 
testing in vivo in animals to confirm the mechanism of 
action and to measure the range of effective dosages 
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and tolerability; and 3) clinical testing in patients to 
define the safe dosage and to confirm the efficacy and 
possible interactions. This process involves serious 
challenges both related to the efficiency, for example 
the development of a human vaccine from concept to 
licensing takes at least 15 years [5], and also to the 
effectiveness. Drug development currently involves a 
99.9% overall failure rate, of which 96.4% is due to 
failure in the preclinical testing phase, meaning that 
the drug efficacy measured in vitro is almost never 
confirmed in animals [6]. 
The main issue is that the most widespread 
technology currently used to test therapeutic agents in 
vitro is obsolete: often it consists of a two-dimensional 
(2D) polystyrene culture dish, in which a single cell 
population is cultured on the bottom, the drug to be 
tested is added to the culture medium, and the 
expected modulation in specific processes or targets is 
measured. 
However, in these simplified in vitro culture 
conditions, the drug elicits a cell response that is not 
representative of the in vivo response, which is based 
on the cell interactions that occur a) in three- 
dimensional (3D) non-flat environments, and b) 
within an heterogeneous cell population which is 
never limited to the cell population primarily 
addressed by the drug. 
Another very serious issue is the unethical 
slaughter of lab animals, which more effective in vitro 
methods would replace, at least in part. Moreover, the 
methods adopted for monitoring the drug effects in 
animals are also obsolete, whereas new miniaturized 
intravital imaging techniques are now available that 
could greatly refine in vivo observations, even in terms 
of the temporal evolution in the same animal, thus 
reducing the number of animals sacrificed by 80-90%. 
There are many on-going clinical trials 
evaluating potential vaccines and treatments for 
COVID-19, which cannot be accelerated without 
putting the safety of patients at risk. Instead, both the 
in vitro and in vivo preclinical phases of drug 
development could be accelerated by replacing some 
of the current unrepresentative and obsolete study 
models, with new ones based on improved modeling 
tools. For example, many groups have developed 3D 
static, microfluidic and intravital imaging models of 
viral infection and relevant therapeutics using new 
high-performance experimental devices that are 
user-friendly for operators and enable live organoids 
to be cultured and examined in 3D with high- 
resolution imaging. 
Here, we review the published work based on 
these modeling tools in the specific fields of virology 
and pharmacology. 
Recent developments 
In silico discovery of drug targets for 
SARS-CoV-2 and prediction of its pathogenic 
mechanisms 
SARS-CoV-2 infection can lead to COVID-19 
infection, which causes massive damage to the 
pulmonary cells [7-11] due to a cytokine storm, i.e. an 
acute secretion of inflammatory signals by innate 
monocytes in response to the infection, which causes 
hyper inflammation. The WHO [12] and 
Clinicaltrials.gov database currently report many 
active trials on COVID-19 patients of drugs that have 
already been licensed for other infectious and 
inflammatory diseases. These include anti-malarial 
drugs, such as chloroquine and its derivative 
hydroxychloroquine, large spectrum antivirals 
(inhibitors of endonucleases, nucleosides, protease 
inhibitors, and other antiretrovirals), interferons, 
corticosteroids, immune suppressants, and 
anticoagulants. 
In parallel, many groups are repurposing known 
compounds and are developing new vaccines [3] and 
therapeutic solutions [4] to specifically target the 
SARS-CoV-2 virus. The drug targets are primarily 
viral proteins, most of which have been resolved and 
are available on the protein data bank (PDB). Much 
progress has been made in the structural biology of 
SARS-CoV-2. Many structural and non-structural 
proteins have been determined experimentally by 
cryo-electron microscopy (cryo-EM) and X-ray 
crystallography. The proteins specific to SARS-CoV-2 
that have already been determined experimentally are 
shown in Figure 1. 
Drug therapies may act either a) on the host cells, 
affecting the specific receptor or restoring the innate 
immunity of the cells, or b) on the virus, by blocking 
the virus functions (I target) or acting on the virus 
structural proteins (II target). The primary (I) drug 
target is represented by several non-structural viral 
proteins (NSPs) whose inhibition blocks the viral 
RNA synthesis and replication [13]. These include the 
papain-like protease (PLpro) in the Nsp3 region, the 
main protease (Mpro) also known as C-like protease 
(3CLpro), the RNA-dependent RNA polymerase 
(RdRp) and the helicase. 
The structural spike protein on the viral 
envelope is the most studied protein of the secondary 
(II) drug targets [13]. The virus cannot bind to the host 
cell receptors, fuse with cell membranes and enter 
cells, if the spike protein is inhibited, and thus it has 
also already been solved by electron microscopy [14]. 
This comprises a receptor binding domain (RBD), 
mainly involved in the host-cell interaction, 
incorporating a sub-domain called a receptor binding 
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motif (RBM) believed to bind, similarly to SARS-CoV, 
mainly with the human angiotensin-converting 
enzyme 2 (ACE2) cell receptor, to gain entry inside 
cells [15]. The ACE2 receptor was discovered in 2000 
and is expressed above all in the lungs, heart, kidneys, 
gastrointestinal tract, testis and other tissues or organs 
[16]. Most drugs against SARS-CoV-2 investigated 
today therefore target the complex RBD+ACE2 
[17-19]. 
Solved SARS-CoV-2 molecular structures have 
been used to set-up docking analyses and molecular 
dynamics simulations that predict the affinity of 
chemical binding of these structures with known 
compounds. This in silico modeling technique has 
been used intensely for drug screening in virtual 
libraries. Table 1 shows the latest published results in 
terms of drugs predicted to bind with SARS-CoV-2 
targets. It is worth noting that most of the in silico 
drug docking analyses listed in Table 1 use the 
homology modelling strategy to predict the structures 
of the target proteins that have not yet been 
experimentally resolved [20-25]. The homology 
modelling approach predicts the atomic-resolution 
model of a target protein based on the structure of the 
protein chosen as a template according to the genome 
sequence identity [26]. The genome of SARS-CoV-2 
showed a high homology with the SARS virus, which 
makes it a reliable template [13]. 
The sequence alignment with the previous 
SARS-like viruses have also been applied to perform 
the virus evolutionary analysis [27], or to highlight 
particular features of the SARS-CoV-2 virus (Table 2). 
Several studies have compared SARS-CoV-2 with 
SARS in terms of interaction of the spike protein with 
the host cell receptor. Structural- and free-binding 
energy-based analyses have revealed accurate details 
of SARS-CoV-2. These observations may explain the 
aggressiveness of SARS-CoV-2, at least in part 
[17-19,28]. 
A similar approach has also been taken to 
explore the efficiency of the binding of the proteins 
encoded by different human ACE2 allelic variants 
with the SARS‐CoV‐2 spike protein. From the binding 
analysis, two variants showed variations in the 
orientation of the amino acid side chain, altering the 
intramolecular interactions and the complex 
formation. This aspect may represent partial intrinsic 
susceptibility or resistance to the SARS‐CoV‐2 
infection [29]. 
 
Table 1. In silico molecular mechanics modeling of drug interaction with SARS-CoV-2 
Refs. Therapeutic agent  Target (Viral subunit) Suggested drug based on the predicted binding energy 
[101] Commercially available antiviral drugs. Mpro, RdRp, helicase, 3'-to-5' 
exonuclease, endoRNAse 2'-O-ribose 
methyltransferase. 
Atazanavir against all the virus endonucleases. 
[20] Sofosbuvin and ribavirin, remdesvir, IDX-184 
guanosine triphosphate, uracil triphoshate, 
cinnamaldehyde, thymoquinone. 
RdRp. Sofosbuvir and ribavirin, remdesivir and IDX-184 were shown to 
tightly bind to the target. 
[21] 7173 purchasable drugs. Mpro. Ledipasvir or velpatasvir (minimal side effects) + Epclusa® 
(velpatasvir/sofosbuvir) and Harvoni® (ledipasvir/sofosbuvir) 
with inhibitory actions on two viral proteases. 
[13] Drug repurposing (ZINC database + database 
of traditional Chinese medicine and natural 
products). 
All the main proteins encoded by 
SARS-CoV-2: 3-chymotrypsin-like 
protease (3CLpro), Spike, RdRp and 
PLpro. 
Remdesivir (GS-5734) inhibitor of RdRp. Its efficacy was verified 
in vitro. It is also hypothesized to inhibit Nsp3b (score=–36.5), 
RdRp (mfScores=–112.8), E-channel (mfScore=–125.1), and 
TMPRSS2 (score=–36.23, mfScores=–109.4). 
[102] FDA-approved drugs against viral protease + 
in-house database of natural and drug-like 
compounds of synthetic origin. 
Mpro FDA-approved drugs: remdesivir, saquinavir, darunavir + two 
natural compounds: flavone and coumarin derivatives. 
[103] Designed inhibitor. ACE2-Spike interface. Designed inhibitors consisting of α1+α2 helixes. 
[104] Designed inhibitor. Mpro. Designed drug that needs to be optimized and tested in vitro and 
vivo. 
[22] Zinc15 - Approved drugs in major 
jurisdictions, including the FDA, i.e. 
DrugBank approved. 
Spike protein + Mpro. Modeled the action of many approved drugs: zanamivir, 
indinavir, saquinavir, remdesivir (against Mpro)+flavin adenine 
dinucleotide (FAD), adeflavin (against both spike and Mpro), and 
coenzyme A (against spike protein). 
[23] Specific drug. Spike via homology modeling (template 
PDB: 2GHV)+spike-ACE2 interaction 
(template: PDB:2AjF). 
Cobicistat, carfilzomib and ombitasvir. 
[24] From a specific drug to its possible target. 20 virus protein + 22 human proteins. Development of molecular docking based webserver, namely 
D3Targets-2019-nCoV for target prediction (in vitro/in vivo 
studies), to identify: (1) the potential target proteins and their 
different conformations were included; (2) all the potential 
ligand-binding sites with volume larger than 200 A°^3; (3) 
correlations among some conformations or binding sites was 
annotated; (4) easily to be updated, and freely accessible. 
[25] Medicinal plant library (32, 297 potential 
anti-viral phytochemicals/traditional Chinese 
medicinal compounds). 
Mpro. 5,7,3’,4’-tetrahydroxy-2’-(3,3-dimethylallyl) isoflavone. 
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Table 2. In silico prediction of the pathogenic mechanisms of SARS-CoV-2 
Refs. Viral/cellular subunit  Modelling method Primary results 
[18] Receptor ACE2 + 
SARS-CoV-2 spike. 
1) Structure alignment between SARS-CoV-2 and 
SARS-COV; 2) SARS-CoV-2 + ACE2 complex 
modeling via single point mutation from solved 
SARS-CoV +ACE2; 3) SARS-CoV-2 and SARS-CoV 
interaction with ACE2 hot spots (residues mainly 
involved in RBD binding) comparison; 4) 
comparison with animals ACE2. 
The two spike proteins are quite similar and therefore the authors analyzed 
in detail the hot spots revealed for SARS-CoV; 2) two virus-binding hot spots 
identified: ACE2 Hot spot 31(salt bridge Lys31-Glu35) and Hot spot 353 (salt 
bridge Lys353-Asp38); 3) (a) SARS-CoV-2 Q493 (vs SARS-CoV N479) was 
compatible but had less of an affinity with hotspot 3, (b) SARS-CoV-2 Q501 
(vs SARS-CoV T487) had less affinity with hotspot 353, but was still 
compatible, (c) SARS-CoV-2 L455 (vs SARS-CoV Y442) preferred interaction 
with Hotspot 31, (d) SARS-CoV-2 F586 (vs SARS-CoV L472) enhances 
interaction with Hotspot 31 (e) SARS-CoV-2 S494 (vs SARS-CoV D480) made 
the interaction weaker but compatible with the hotspot 353; 4) mouse or rat 
ACE2 contained a hotspot at the 353 position, which did not fit into the RBD 
of SARS-CoV-2 which instead recognized ACE2 from pigs, ferrets, cats, 
orangutans, monkeys, and humans. 
[19] Receptor ACE2 + 
SARS-CoV-2 spike. 
1) Genomic analysis; 2) homology modeling for 
SARS-CoV-2 spike; 3) structural superimposition in 
SARS-CoV+ACE2 model; 4) binding free energy 
evaluation. 
1) Low homology in RBD domain between SARS-CoV-2 and SARS-CoV, but 
high similarity (similar polarity); 2) From free energy binding the authors 
observed that even though it was weaker than SARS-CoV (–78.6 kcal mol–1), 
SARS-CoV-2 spike still showed an high affinity with ACE2 (–50.6 kcal mol–
1); 3) Differences in aa sequences did not alter the protein conformation and 
maintained similar Van der Waals and electrostatic properties. 
[17] receptor CD26 + 
SARS-CoV-2 Spike. 
1) Homology modeling for SARS-CoV-2 Spike 
(S1+S2) using the SARS-CoV as template (PDB: 
6ACD) to obtain inactive configuration and using 
SARS-CoV+ACE2 complex structure as a template 
(PDB:6ACG) to obtain the active structure; 2) 
analysis of glycosylation sites via the server; 3) 
comparison (SARS-CoV-2 vs SARS-CoV) of the 
glycosylation shield structure obtained by server; 4) 
docking between the modeled trimeric spike and 
human CD26 (PDB: 4QZV).  
1) SARS-CoV-2 Spike tetramer configuration in both active and inactive state; 
2) Based on the Spike+ACE2 model the authors identified the 3C-like 
proteinase cleavage site + glycosylation sites; 3) from SARS-CoV and 
SARS-CoV-2 comparison: SARS-CoV-2 showed several unique glycolysation 
sites in addition to the conserved from SARS-CoV. This suggested a different 
shielding or camouflage pattern; 4) SARS-CoV-2 spike showed a large 
interaction surface with CD26 with many unique residues (different in 
SARS-CoV) involved in the interaction. SARS-CoV-2, compared to previous 
SARS-CoV viruses, interacts in a different way with the human receptors. 
[28] ORF1ab (Nsp2 and 
Nsp3). 
Provides information on how quickly the virus 
could potentially increase its genetic variability, 
with implications for contagiousness and drugs via 
comparison of ORF1ab SARS structure: 1) The 
ORF1ab of 15 SARS-CoV-2 sequence alignment 
with five sequences of SARS virus and five 
sequences from Bat SARS‐like virus; 2) selective 
pressure analysis; 3) homology modeling for NSp2 
Nsp3; 4) trans-membrane analysis. 
Potential sites under positive selective pressure were found (501); 
transmembrane helices were predicted. At the residue 501, Bat SARS‐like 
coronavirus showed an apolar amino acid (threonine), while SARS and 
SARS-CoV-2 showed a polar amino acid, glycine and glutamine, 
respectively. Hypothesis: polarity, and potential to form H‐bonds may confer 
higher stability to the protein. 723 aa. SARS-CoV-2 sequence showed a Serine 
replacing for Glycine in Bat SARSlike and SARS coronaviruses. Hypothesis: 
substitution increases the local stiffness of the polypeptide chain due to a 
steric effect and to the ability of Serine side chain to form H‐bonds. At 1010 
aa, SARS-CoV-2 has Prolin, the Bat SARS‐like coronavirus and SARS virus 
showed a polar and an apolar a. Hypothesis: steric bulge and stiffness of the 
Proline may cause local conformation perturbation compared with the 
proteins of the other two viruses. 
[27] Spike-ACE2. Prediction of the interaction ACE2 RBD-spike. 
Evolutionary analysis and search for the possible 
virus reservoirs. Comparisons of the spike 
sequences between SARS‐CoV‐2 with SARS‐CoV, 
Bat SARS‐like CoV, and other coronaviruses. 
Analysis of the ACE2 structures and binding motif 
alignment:1) Alignment of spike protein sequences 
from different sources. Full-length and RBD 
sequences of spike protein from SARS‐CoV, bat, or 
pangolin SARS-like CoV and SARS‐CoV‐2 were 
aligned; 2) comparison of ACE2 enzyme among 
different species; 4) prediction of spike protein 
model and spike‐ACE2 binding model. 
Bat SARS‐like CoV RaTG13, is an inner joint neighbor of SARS‐CoV‐2 (6.2% 
overall genome sequence identity); the full‐length sequence of S pangolin 
SARS‐like CoV and SARS‐CoV‐2 seem to be a little different but SARS‐CoV‐2 
RBD sequence (329 to 521) like CoV, had a higher than 89% similarity with 
bat SARS‐like CoV; pangolin SARS‐like CoV has a higher probability to cross 
host barriers and infect humans; from infection-involved aa comparison, 
they identified pangolins, turtles as possible intermediate hosts. 
[26] ORF1ab. 1) The authors showed a typical workflow for 
homology modeling applied to the SARS-CoV-2 
ORF1ab proteins; 2) aa sequence comparison. They 
performed sequence alignment investigations on 10 
primary sequences of SARS-CoV-2 via BLAST, 
SWISS‐MODEL, and Clustal Omega. 
1) According to BLAST analysis, the sequence identity of ORF1ab protein 
between SARS-CoV-2 and SARS‐CoV was over 90% with the query cover of 
about 100%; 2) the authors showed a typical workflow for homology 
modeling applied to the SARS-CoV-2 ORF1ab proteins. 
[29] Spike + ACE2 receptor. This study explores the binding of the proteins 
encoded by different human ACE2 allelic variants 
with SARS‐CoV‐2 spike protein. 1) They selected 
the coding variants of ACE2 and predicted in silico 
the possible allelic variants; 2) they modelled the 17 
obtained coding variants of ACE2 via homology 
modeling with native structure and superimposed 
the structures for comparison; 3) They 
superimposed the obtained models over the native 
ACE2‐spike protein complex; 4) inter‐residual 
interaction maps. 
1) The authors selected the allelic structures involved in the ACE2-spike 
interaction (17 variants); 2) The protein architecture of ACE2 allelic variants 
was similar to the wild type but the spatial orientation of substituting 
residues varied notably; 3) ACE2 variants bind with spike protein identical to 
the native complex + intermolecular contacts between SARS‐CoV‐2 spike 
protein and ACE2 variants are comparable. Among the differences, 
rs73635825 (S19P) and rs143936283 (E329G) showed a low binding affinity, 
which may confer resistance against the virus infection. 
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Figure 1. Drug targets specific to the SARS-CoV-2 virus. A) The SARS-CoV-2 whole genome consists of three main open reading frames (ORF): ORF1a, ORF1b and 
ORF2-10. The most frequent targets for therapies are reported in gray with their PDB codes. B) Some proteins encoded in ORF1a and ORF1b represent the primary I potential 
drug target. Their inhibition blocks the viral RNA synthesis and replication. Pp1ab encodes for 16 non-structural proteins (NSPs) including the papain-like protease (PLpro) in the 
Nsp3region, main protease or C-like protease (Mpro or 3CLpro), ADP ribose phosphatase (ADRP), RNA-dependent RNA polymerase (RdRp) and helicase. ORF2-10 encodes 
for accessory proteins (e.g. 7a) and the structural and accessory proteins, spike protein (S), envelope protein (E), membrane protein (M), and nucleocapsid protein (N). C) The 
spike protein is the most studied secondary II potential drug target. The virus cannot bind the cell receptors if the spike protein is inhibited [14]. The spike protein has been 
studied the most, has been solved by electron microscopy (EM) and consists of: N-ter domain (NTD); receptor binding domain (RBD) consisting of receptor binding motif (RBM), 
subdomain 1 (SD1) and subdomain 2 (SD2); fusion peptide (FP); heptad repeat 1 (HR1); heptad repeat 2 (HR2); transmembrane region (TM) and intracellular domain (IC). The 
most studied RBD domain is RBM (in red), the domain mainly involved in host-cell interaction [13]. RBM is believed to bind mainly with the ACE2 human cell receptor and, 
therefore, most of the relevant PDB codes, of which 6M0J, includes the RBD+ACE2 complex. The complete amino acid sequence for RBD is shown at the bottom of the figure. 
Amino acids corresponding to RBM are in red, the beta-sheet and alpha-helix structures are inside the dotted boxes. The contact residues at the RBD/ACE2 interface [14] are 
shown in bold squares. *https://www.ncbi.nlm.nih.gov/genbank/sars-cov-2-seqs/. 
 
3D cell models to improve pre-clinical in vitro 
studies 
Once discovered in silico, the drug has to be 
tested in vitro and in vivo in experimental models of 
viral infection. 
Our aim was to include any advanced study 
model developed for virology and vaccinology since 
the SARS coronavirus outbreak of 2003 and we 
analyzed the literature pertaining to the last two 
decades. We found 40 papers, 75% of which were 
published in the last five years. 3D cell models are 
generally based on cell aggregates or organoids, 
cultured within a matrix or scaffold that provide a 3D 
environment for cell growth (Figure 2). Organoids are 
usually obtained starting with pluripotent stem cells 
(most frequently iPS), while engineered tissues are 
mainly derived from multipotent or unipotent cells. 
To date, only five very recent studies have 
addressed SARS-CoV-2 with such an innovative 
approach: specifically they replicate the SARS-CoV-2 
infection in models of the human airway epithelium 
[30-32], human liver organoids [33] and in engineered 
human kidney and vessel organoids [34]. In addition, 
three of the above studies include therapeutic agents 
to inhibit SARS-CoV-2 infection: clinical-grade human 
recombinant soluble angiotensin converting enzyme 2 
(hrsACE2) [34], remdesivir also in association with 
diltiazdem [31] and β-D-N4-hydroxycytidine [32]. 
Table 3 reports the findings of the published 3D cell 
models used to study viral infections, and Table 4 
reports those that also include the effects of an 
antiviral therapy. 
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Figure 2. Micro-fabricated “Nichoid” scaffold for 3D cell culture. A) Nichoid architecture. From left to right: scanning electron microscopy (SEM) image of a Nichoid 
single-module; SEM image of up-scaled repetitive matrixes of Nichoids; picture of 50 mm2 micro patterned glass coverslip with Nichoids. Nichoid culture 3D-substrates are 
produced via two-photon laser polymerization of SZ2080 negative photoresist with near-infrared exposure following a CAD geometry. B) Possible microscopy configurations 
to use on Nichoid culture substrates. Thanks to the device's versatility, this scaffold enables optical accessibility both in transmission and in reflection modality. C) 
Immunofluorescence images obtained via confocal fluorescence microscopy of GFAP (red), β-ACTIN (green) and DNA (blue), in human Adipose derived Stem Cells (hADSCs) 
after a 7-day expansion inside the Nichoid and in standard conditions (2D-Control). The images demonstrate that nuclear morphology and protein organization and localization 
(both β-ACTIN and GFAP) differed between the two culture systems. Cytoskeletal markers merge (yellow signal) into cellular protrusions inside Nichoids, while a poor signal 
appears in flat conditions. D) Real-time PCR analysis of specific gene targets shows a significant gene expression difference (up-regulated in green, and down-regulated in red) 
between Nichoid and Control conditions, both using a standard culture medium and also using a culture medium that induces adipogenic or neural differentiation. 
 
Table 3. In vitro 3D cell models of viral infection 
Refs. Pathogen Cell type/s Cell culture configuration 
[30] SARS-CoV-2. Primary human epithelial cells from airway 
epithelium. 
Epithelial cells were isolated and expanded in transwells, then an 
air-liquid-interface (ALI) model was provided with a pseudo-stratified 
and fully-differentiated system, showing basal, ciliated and goblet cells 
which secreted mucus and proteins. 
[33] SARS-CoV-2. Primary human cholangiocytes from 
primary bile ducts. 
Liver ductal organoids (LDO) embedded in Matrigel. 
[46] MERS-CoV. Primary human intestinal epithelial cells, 
LGR5+ intestinal adult stem cells and Caco2 
cells. 
A) 2D epithelial intestinal cell (2D/EICs) differentiation for 7 days. B) 
Human intestinal tissue (HTI) excised and maintained in transwells coated 
with Matrigel. C) Intestinal Organoid from LGR5+ cells embedded in 
Matrigel. D) Caco-2 cells seeded on transwells and polarized (2 weeks). 
[105] Zika virus. Primary human testicular cells: 
spermatogonial stem cells (SSC), Sertoli cells 
(SC), Leydig cells (LC) and peritubular cells. 
Human testicular organoid (HTO): SSC, SC, LC and peritubular cells 
centrifugated and seeded in ultra-low attachment plate maintained with 
medium + testis ECM after 48 h self-assembled in spheroids. 
[35] Respiratory syncytial virus 
(RSV). 
Human iPSCs from fetal tissue. Lung bud organoid (LBO) from hPSCs embedded in Matrigel and induced 
to anterior foregut endoderm differentiation (CD184+ +CXCR4/c-KiT) and 
airway branch formation. 
[36] Respiratory syncytial virus 
(RSV). 
Primary epithelial cells isolated from 
non-small cell lung cancer. 
Cells were embedded in basement membrane extract (BME) and grown as 
adult human epithelial airway organoids (pseudostratified airway 
epithelium with basal, secretory, multi-ciliated cells). 
[37] Avian influenza (IAV) 
H1N1/H3N2. 
Primary human small airway epithelial cells 
(SAEpCs). 
HSAEpCs were loaded onto a 3D chitosan-collagen scaffold and exposed 
to air-liquid interface (ALI) on the upper part of transwell, alternatively the 
cells were totally covered with media. 2D culture conditions were 
performed by seeding cells directly on the upper part of a transwell plate 
replicating the same ALI and immerged conditions as the 3D one. 
[38] Avian influenza (IAV)  
(H1N1 - H7N9/Ah - H5N1 - 
H7N2 -H7N9/ah). 
Human lung resident adult stem cells (ASC). Airway organoids and proximally differentiated airway organoids (AO) 
made by ASCs embedded in Matrigel and grown in transwells for 16 days. 
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Refs. Pathogen Cell type/s Cell culture configuration 
[39] Parainfluenza virus-3 (HPIV3) + 
measles virus (MeV). 
A) Human airway epithelium (HAE) system: 
normal human derived trachea/bronchial 
epithelial cells; B) Organoid system: 
embryonic stem cell line 2 (RUES2) + feeder 
layer mouse embryonic fibroblasts. 
A) HAE system: epithelial cells cultured to form a highly differentiated 
pseudostratified mucociliary epithelium; B) lung bud organoids grown to 
the last-second trimester of lung development (LBO): endoderm (c-KiT, 
CXCR4 positive)+anterior endoderm foregut formation + ventralization 
inductions followed by branching airways formation after Matrigel 
embedding. 
[45] Measles virus (MeV). Human primary fibroblast (FBCs)+H358 
lung adenocarcinoma epithelial cell 
line+dendritic cells (DCs) human primary 
monocytes. 
Decellularized porcine small intestinal submucosa (SIS) seeded on the 
apical side with FBCs and H358-eFLUOR670 cells, DCs-GFP+ and 
DCs-GFP- added in suspension on the basolateral side. 
[48] HIV-1 virus. Primary human CD4+ T-lymphocytes. Cells were loaded in custom-made collagen type I gels derived from rat tail 
and bovine. 
[40] Andes-hantavirus (ANDV). Human lung fibroblast MRC-5+h-bronchial 
epithelial cells 16HBE14o-. 
Layered construct in transwell system: bottom bovine collagen-I, MRC-5 + 
b-coll-I, top 16HBE14o- guarantee air-liquid interface (ALI). ANDV 
inoculated from the apical side of the construct. 
[41] Human rhinovirus C (HRV-C) 
and human bocavirus (HBoV). 
Human primary epithelial cells (HAE). 2D culture systems provided via HAE seeding in monolayers. 3D model 
obtained seeding HAEs in 4 different ways on transwells coated with 
Matrigel. 3D possible configurations of HAEs were: ON, WITHIN, ON and 
WITHIN and UNDER Matrigel. 
 
 
Most studies on viruses other than SARS-CoV-2 
consist in modeling respiratory infections diffused in 
an engineered human pseudostratified airway 
epithelium [35-44]. In these models, the cellular 
constructs are based on primary epithelial cells 
embedded in a matrix of biological origin replicating 
the basal membrane, and are grown to full 
differentiation, preferably at the air-liquid interface, 
into an organoid with basal, secretory, and 
multi-ciliated cells. Most studies also use specific 
control cell lines cultured in monolayer, for example 
derived from lung and intestinal adenocarcinoma 
epithelial cells [32, 45-46], or from lung primary 
fibroblasts and epithelial cells [40]. A comparison of 
the results from 3D models with monolayer cultures 
highlights the following significant advantages of 3D 
cell models in replicating conditions observed in vivo. 
1) Cell morphology, virus penetration and cell damage 
These parameters can be imaged and are 
replicated similarly to in-vivo in 3D cell and organoid 
models, unlike in cell monolayers. For example, cells 
in 3D engineered airway epithelium infected with 
SARS-CoV-2 showed apical-apical polarity, which is 
known to restrict the infection to the airway lumen in 
vivo [30], and reproduced infection peaks and 
significant morphological alterations earlier in nasal 
cells compared to bronchial cells [32]. Cells in liver 
organoids infected by SARS-CoV-2 [33] and cells in 
intestinal organoids infected by MERS-CoV [46] had 
syncytia and membrane fusions as observed in mice 
in vivo models. When infected by the respiratory 
syncytial virus (RSV), lung organoids had a 
morphological structure and infection features 
matching human fetal lung tissue [35], and airway 
epithelium organoids had massive epithelial 
modifications as in mature tissue infection in vivo [36]. 
In a 3D engineered airway epithelium, cell 
morphology was close to in-vivo characteristics, with a 
reorganization of cytoskeletal components, an 
abundance of ciliated cells [38], and a mucociliary 
layer [41], with surfactant and mucus often produced 
[37]. Here, the H7N9 influenza virus infected both 
ciliated and non-ciliated cells, causing cilia and tight 
junction damage seen in vivo [42]. A 3D engineered 
liver model reproduced and demonstrated greater 
physiological hepatocyte morphology, polarity, and 
apical/basal adhesion to ECM compared to a classical 
cell monolayer [47]. 
2) Susceptibility to viral infection 
3D cell and organoid models are significantly 
more permissive to viral infection, compared to cell 
monolayers. For example, when infected by SARS- 
CoV-2, the peak infection in 3D-engineered human 
airway epithelium was reached 30% faster [31]; also, 
when infected by avian influenza virus H7N9, viral 
proliferation was faster [42]. In addition, propagation 
of human rhinovirus C and bocavirus was two and 
three orders of magnitude greater, respectively [41]. 
In airway epithelium organoids infected with avian 
influenza virus such as H1N1, the viral proliferation 
was faster and with a time-order equivalent to the in 
vivo proliferation time [38]. MERS-CoV was shown to 
infect intestinal organoids more than epithelial 
monolayers [46]. In a model of HIV-1 infection of 
primary human CD4+ T-lymphocytes, 3D collagen 
culture, unlike suspension conditions, promoted 
cell-associated HIV-1 transmission, consistent with 
spread mechanisms described in vivo [48]. Human 
intestinal organoids infected with rotavirus displayed 
a 10,000-fold increase in genomic viral RNA than cells 
infected in monolayer [49]. Hepatitis B replicated one 
order of magnitude faster in a 3D-engineered liver 
model, compared to a cell monolayer [47]. 
Theranostics 2020, Vol. 10, Issue 15 
 
 
http://www.thno.org 
7041 
Table 4. In vitro 3D cell models of viral infection and evaluation of antiviral therapy effects 
Refs. Pathogen Therapeutic agent  Cell type/s Cell culture configuration 
[31] SARS-CoV-2. Remdesivir, remdesivir + 
diltiazem. 
A) Vero E6 cell line for monolayer 
culture, B) nasal and bronchial human 
primary epithelial cells for 
pseudostratified epithelial model. 
A) Vero E6 cultured in standard static condition, B) cells 
after isolation cultured in transwell inserts to reach a full 
differentiation until pseudostratified mucociliary 
epithelium (human airway epithelium HAE). 
[32] SARS-CoV-2, 
SARS-CoV, 
MERS-CoV. 
β-D-N4-hydroxycytidine 
(NHC, EIDD-1931). 
A) 2D model with Calu-3 human lung 
epithelial cell line; B) human primary 
tracheobronchial epithelial cells (HAE). 
Human airway epithelium cultures (HAEs) were generated 
by an air-liquid interface for 6 to 8 weeks to form well- 
differentiated, polarized cultures that resembled in vivo 
mucociliary epithelium. Primary cells were expanded and 
plated at a density of 250,000 cells per well on 
transwell-COL (12mm diameter) supports. 
[34] SARS-CoV-2. Human recombinant soluble 
angiotensin converting 
enzyme 2 (hrsACE2). 
iPSCs and human embryonic stem cells 
(hESCs). For bidimensional culture: 
Vero-E6 cells. 
Human capillary organoids from iPSCs and kidney 
organoids form hESCs. 
[42] H7N9 influenza A 
virus. 
Recombinant human 
interferons α2b (rhIFN-α2b) 
and λ1 (rhIFN-λ1). 
Well-differentiated pseudostratified 
human airway epithelium (HAE) cells; 
controls: A549 adenocarcinomic human 
alveolar basal 
epithelial cell line. 
All cell types were grown at the air–liquid interface: 2D 
HAE in monolayer on collagen, 3D HAE in 
pseudostratified layers on transwell; A549 on transwell. 
[43] Rhinovirus species 
(RV-A16, RV-B14 
and RV-C15); 
enteroviruses 
EV-D68 and 
influenza A (H1N1 
and H3N2). 
Rupintrivir, an irreversible 
inhibitor of human 
rhinovirus protease, was 
chosen as a reference drug. 
Oseltamivir, a 
neuraminidase inhibitor, 
approved to treat and 
prevent influenza infections. 
Airway cells were obtained from 14 
different patients undergoing surgical 
polypectomy. 
Cells were cultured at the air–liquid interface in MucilAir 
culture medium in 24-well plates with 6.5-mm transwell 
inserts.  
[44] Syncytial virus 
(RSV). 
Entry/fusion inhibitors 
(GS-580619 and 
TMC353121); nucleoside 
viral polymerase inhibitor; 
two non-nucleoside 
replication inhibitors 
(AZ-2721 and PC786). 
Fully-differentiated human airway 
epithelium cells (HuAECs) of bronchial 
origin from healthy donors. 
HuAECs of bronchial origin were seeded in an air–liquid 
interface cell culture system with MucilAir medium. 
[49] Rotavirus. Interferon-alpha (IFN-α) 
and ribavirin. 
For mouse and human organoids: 
resection on small intestine of mouse and 
intestinal biopsies or surgically resected 
intestinal tissues for patients; for 2D 
culture: Caco2 cell line. 
The crypts obtained from the biopsies were suspended in 
growth factors reduced phenol-red free Matrigel. This was 
placed in the center of each well of a 24-well plate and was 
subsequently incubated with a specific culture medium. 
[47] Hepatitis B (HBV). Entecavir. HepG2-NTCP cell line (transfected cell 
line for HBV infection) + primary human 
hepatocytes (PHHs). 
Human decellularized liver scaffold from healthy and 
cirrhotic donors (hDCS-hDLCS) seeded with PHHs and 
with HepG2-NTCP. 
[50] Herpes Simplex 
virus 1 (HSV-1). 
Antivirals 5BVdU and 
interferon-alpha (IFN-α). 
Human fibroblast derived iPSCs and 
HFF1S cell lines. 
2D neural culture obtained by hiPSCs seeded and cultured 
with neurobasal medium and brain neurothrophic factor to 
become neural progenitor cells (NPCs) and mature 
neurons. 3D brain organoids obtained via hiPSCs 
differentiation towards NPCs self-assembled 
neurospheroids in transwell and maturing in a toroidal 
shape while cultured in low-attachment plates. 
[51] Herpes simplex 
virus-1 (HSV-1). 
Acyclovir (ACV). 3T3 fibroblasts; for viral stock: Vero cell 
lines. 
In vitro 3D acrylated hyaluronic acid (AHA) hydrogel 
model encapsulating fibroblasts. 
[99]  Herpes simplex 
virus type 1 and 
type 2 (HSV) and 
varicella-zoster 
virus (VZV). 
Acyclovir, penciclovir, 
brivudin, foscarnet, and 
cidofovir. 
Primary human keratinocytes isolated 
from neonatal foreskins. 
Organotypic epithelial raft cultures that permit full 
differentiation of keratinocyte monolayers. The cells were 
cultures on collagen gels at the air-liquid interface. 
[100] Cowpox virus. Gefitinib. Pooled primary normal human 
epidermal keratinocytes (NHEK); for 
viral stock: HEp-2 cells and Vero E6 cells. 
For 3D culture, decellularized equine pericardium used as 
a biological ECM for cell culture of 1×105 NHEK cells. For 
monolayer control, NHEK were seeded in 24-well cell 
culture plates. 
 
 
3) Cell expression of virus receptors, antiviral genes, 
antigens to viruses and inflammatory markers 
The expression of all these markers is more 
similar in time and space to in-vivo values, in 3D cell 
and organoid models, compared to cell monolayers. 
For example, a 3D-engineered airway epithelium 
infected by SARS-CoV-2 showed different expression 
levels of immune-response genes (type I and type III 
interferons and a subset of genes associated with the 
NF-kB and TNFα pathways) between nasal cells (with 
strong upregulation at 24 hours post infection) and 
bronchial cells (with low expression) [31]. Cells in 
liver organoids expressed the ACE2 receptor, thus 
enabling SARS-CoV-2 infection, unlike in the mouse 
model [33]. When infected by the respiratory syncytial 
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virus (RSV), lung organoids had gene and marker 
expression (primarily the mesenchymal markers 
PDGFR-α, PDGFR-β, α-SMA, vimentin and CD90) 
that matched infected human fetal lung tissue [35], 
while airway epithelium organoids expressed levels 
of genes involved in migration (KRT16, KRT6b), 
interferon signaling (IL1RN, IFI44L) and viral 
response (MX2, OAS1), comparable to in vivo values 
[36]. 
In 3D-engineered airway epithelium, expression 
of inflammatory cytokines (aquaporin-5 and 
cytokeratin-14) was two-fold higher than monolayers 
when infected with avian influenza viruses H1N1 and 
H3N2 [37], and two orders of magnitude higher (for 
IL-6 and IL-8) when infected with human rhinovirus 
C and human bocavirus [41], closely recapitulating 
the immune response seen in vivo. In a model of 
stratified airway epithelium infected by the 
andes-hantavirus, long-term culture at seven days 
showed a switch in immune response from anti-viral 
(transient interferon) to antinflammatory (cytokines 
and VEGF-A), as occurs in-vivo [40]. Hepatitis B 
induced a two-fold higher expression of specific 
antigens (HBsAg) in a 3D-engineered liver model, 
compared to cell monolayers [47]. 
4) Sensitivity to antiviral drugs 
In 3D models, the sensitivity to antiviral drugs is 
significantly lower and more similar to in vivo than 
cell monolayer observations. For example, the efficacy 
of clinical-grade soluble human ACE2 in reducing 
SARS-CoV-2 infection in both human capillary 
organoids and kidney organoids was one order of 
magnitude lower than in monolayers [34]. In a 
3D-engineered airway epithelium infected with the 
H7N9 influenza virus and treated with recombinant 
human interferons α2b and λ1, the expression of 
interferon-stimulated antiviral genes was significantly 
reduced, and the level of gene expression induced by 
the two agents was reversed, consistently with data in 
vivo, compared to monolayers [42]. Human intestinal 
organoids infected by human rotavirus, compared to 
the simple cell line model in monolayers, were twice 
less sensitive to interferon α and ribavirin, with a 
range of effective doses comparable to that 
administered in in vivo models [49]. 
The response to the antiviral drug entecavir in a 
3D human engineered liver model infected by 
hepatitis B was more similar to in vivo, compared to 
the cell line model [47]. In conventional cell 
monolayers, the response of herpes simplex infection 
to antivirals is unrealistically fast with 100% 
reactivation. For herpes simplex 1, virus reactivation 
after exposure to interferon α was reduced five-fold in 
infected 3D brain organoids compared to cell 
monolayers, as reported in animal models [50]. In 
addition, in hydrogels made of acrylated hyaluronic 
acid and loaded with fibroblasts, the time for cell 
recovery and reaggregation after infection and 
exposure to the antiviral drug, acyclovir was 
three-fold greater than in cell monolayers, similarly to 
in vivo [51]. 
The evidence outlined above shows that 3D cells 
and organoid models consistently develop properties 
that are able to determine the in vivo-like dynamics of 
infection by pathogenic viruses. They thus may 
represent a valuable tool towards a more rapid 
assessment of infectivity to humans of emerging 
respiratory viruses such as the SARS-CoV-2, and of 
relevant drug responses. 
From a technological point of view, there are two 
principal limitations of the previously analyzed 3D 
models compared to conventional monolayer models, 
which are essentially related to the 3D scaffolds. The 
current scaffolds are mainly represented by either 
hydrogels [52-53] or solid ECM analogues [54], which 
are placed on the bottom of culture plates or in trans- 
well inserts, resulting in constructs which are a few 
millimeters thick and cannot be examined under 
optical microscopy. The second problem in current 3D 
scaffolds is the very limited control over the culture 
time of some physical and chemical properties known 
to profoundly affect cell behavior, such as 
biodegradation with the release of various solutes, 
and mechanical properties such as stiffness, which 
influence cell adhesion and migration [54]. To 
overcome all these limitations, many groups of 
researchers are developing miniaturized 3D scaffolds 
by a cutting-edge fabrication technique called 
two-photon laser polymerization [55]. 
For example, our group has developed an 
innovative 3D micro-scaffold called the Nichoid 
(Figure 2), which is optically and physically accessible 
to the cells cultured inside, over time, and to all the 
existing biological assays. The Nichoid is a 
miniaturized rigid, transparent, ultra-precise 3D grid 
fabricated in a biocompatible resin [56-58]. This 
scaffold is up to 100 microns thick, thus truly 3D for 
cells but 100% optically accessible to high-resolution 
fluorescence diagnostics. By mimicking the 3D 
stiffness of a physiological cell niche [59], the Nichoid 
can guide the self-organization of several types of 
stem and progenitor cells [60-61], including 
embryonic stem cells [62] and mesenchymal stem cells 
(MSC) [63]. It also maintains their phenotype in 
expansion culture, by regulating hundreds of genes 
involved in mechanotransduction processes such as 
cell migration, cytoskeletal organization, and 
membrane plasticity [64]. The Nichoid could thus 
provide an effective culture environment to test 
Theranostics 2020, Vol. 10, Issue 15 
 
 
http://www.thno.org 
7043 
mechanobiological effects such as the overexpression 
of interferon-induced transmembrane proteins that 
can rigidify the cell membrane, thus markedly 
inhibiting viral membrane fusion and entry. It could 
thus be used for screening candidate antiviral drugs 
and vaccines based on the targeting coronavirus spike 
protein. We also observed that the Nichoid 
potentiates the therapeutic efficacy of stem cells 
expanded inside [65]. This substrate is a powerful 
candidate to maintain the safety and function of 
expanded MSC [63], which is a new therapy already 
being tested in clinical trials to treat post-COVID-19 
pulmonary fibrosis [66]. 
Bioreactor-perfused cell models 
In bioreactor culture systems, the cellular 
constructs or organoids are hosted in culture 
chambers, which are connected to a hydraulic circuit 
that perfuses the culture medium with a pump 
(Figure 3). Microfluidic systems are the miniaturized 
version of bioreactors, generally consisting in thin 
transparent devices, similar to microscopy slides, with 
integrated micro-channels that can host cell-loaded 
hydrogels or suspensions. Table 5 shows the viral 
infection models that have been developed using 
bioreactor devices. The literature reports a pioneering 
model of SARS-CoV infection in a 3D 
bioreactor-engineered respiratory epithelium [67-68] 
and several other more recent models of infection 
based on different types of viruses. These studies 
demonstrate the following significant advantages of 
perfused culture in replicating conditions seen in vivo, 
compared to non-perfused culture. 
1) Perfusion increases the degree of cellular 
differentiation 
For example, a 3D bioreactor-engineered 
respiratory epithelium infected with SARS-CoV was 
found to more closely resemble normal human tissue 
in terms of cell apical polarity, essential to viral 
cell-cell transport, compared to non-perfused culture 
[67-68]. A bioreactor-engineered liver model of 
hepatitis B infection recapitulated the functional 
hepatic microarchitecture and complete cell 
polarization, which is critical for the cells’ 
susceptibility to infection, compared to non-perfused 
organoids which show de-differentiation over 10-13 
days [70]. A bioreactor-engineered model of neuronal 
tissue based on neural progenitors showed some 
features of the human trigeminal ganglia, the site of 
latency of the varicella-zoster virus, not seen in 
non-perfused cultures [68-69]. 
 
 
Figure 3. Millifluidic optically accessible bioreactor (MOAB) for perfused culture of 3D cell constructs. A) The system is composed of, from left to right: culture 
medium reservoirs, microfluidic pumps, bioreactor chamber and reservoirs for medium collection. CAD model of the 3D cell construct or organoid, cultured in the culture 
chambers, used for numerical simulations. B) Results of the computational fluid dynamics (CFD) simulations for a single culture chamber of the system. Top: fluid velocity 
(modulus of the velocity vector) is mapped on the whole culture chamber. Bottom: wall shear stress (WSS) is computed and mapped at the cell-culture medium interface. C) 
Photo of the MOAB showing the three independent chambers connected to the perfusion chamber by oxygenator tubes; the device is placed on a confocal microscope 
connected to a CPU allowing real time imaging of a perfused lymph-node-on-a-chip model, for the development and testing of vaccines and agents for cancer immune-therapy. 
D) Fibroblast reticular cells (yellow) are seeded on the 3D fiber scaffold. Dendritic cells introduced in suspension during culture medium flow adhere to the fibroblast reticular 
cells, migrate to the scaffold, and are activated to express the adhesion receptor ICAM-1 (red). E) Antigen-specific T cells (cyan) introduced with culture medium flow tend to 
adhere to dendritic cells expressing ICAM-1 (red) while crawling on the scaffold. 
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Table 5. In vitro cell models of viral infection based on bioreactor-perfused cultures 
Refs. Pathogen  Cell type/s Cell culture configuration 
[67-68] SARS-CoV. Primary human bronchial-tracheal cells (HBTCs) used to 
establish a human lung tissue-like assembly (TLA) with an 
overlay of human bronchial epithelial (BEAS-2B) cells. 2D 
control established with BEAS-2B monoculture. 
3D tissue dynamic culture system established using a Rotating Wall 
Vessel (RWV) bioreactor. Static 2D controls: tissue culture flasks of 
near confluent BEAS-2B monocultures. 
[70] Hepatitis B virus 
(HBV). 
Primary Human Hepatocytes (PHH) and co-culture with 
primary Kupffer cells (KC). 
Perfused 3D bioreactor. Medium was recirculated via a 
pneumatically driven micro-pump, and collagen-coated scaffolds 
were used for cell adherence. Each plate consisted of 12 individual 
bioreactors, in which the flow rate was regulated. 3D perfused: PHH 
seeded in 3D scaffolds. Non-perfused controls: 3D spheroid, static 
2D PHH, and self-assembling co-cultures (SACC) of PHH. 
[68-69] Varicella zoster virus 
(VZV). 
Normal human neural progenitor (NHNP) cells used to 
establish human neuronal tissue- like assembly (TLA). Gene 
mutations, infection study and VZV genome maintenance 
were performed on the TLA and validated with a 2D control 
of human melanoma (MeWo) cells. 
Optimized 3D tissue culture systems created using a Rotating Wall 
Vessel (RWV) bioreactor. The 3D model was compared to a 2D 
control of NHNP cells. 
[71] Adenovirus carrying 
enhanced green 
fluorescent protein 
(AdEGFP). 
Mouse embryonic fibroblasts (MEFs) and human foreskin 
fibroblasts (HFFs) both for microfluidic study and static 
control. 
Microfluidic device composed of a supporting glass slide with a 
PDMS slab carved to accommodate the cell culture coverslip, a 
membrane-based vacuum system for the reversible sealing, and 
microfluidic channels delivering fluids to the cultured cells. The 
control was performed in static conditions. 
[106] Enhanced green 
fluorescent protein 
(EGFP) plasmid. 
3T3 fibroblasts used for 2D control, static and dynamic 
conditions. 
Microfluidic perfused device for dynamic cell culture and virus 
infection in a micro channel, control was performed in 2D 
conventional culture, and in the microfluidic device was evaluated 
in both static and dynamic conditions. 
 
 
2) Perfusion extends cell viability, cell metabolism and 
functional stability 
A 3D bioreactor-engineered respiratory 
epithelium infected with SARS-CoV remained viable 
three-times longer than non-perfused controls [67-68]. 
A bioreactor-engineered liver model of hepatitis B 
infection was metabolically and functionally stable for 
at least 40 days, i.e. four times longer than 
conventional non-perfused cultures [70]. A bioreactor- 
engineered model of neuronal tissue infected by the 
varicella-zoster virus was successfully maintained in 
culture for 180 days, compared to the limit of a few 
days for primary human ganglia in non-perfused 
culture [68-69]. 
3) Perfusion increases the infection efficiency for 
longer incubation times 
In a microfluidic model of fibroblast infection by 
the adenovirus, a 50% higher infection efficiency was 
maintained at a lower multiplicity of infection (the 
minimum virus/cell ratio able to cause infection) for 
longer incubation times, with respect to non-perfused 
controls [71]. A bioreactor-engineered liver model of 
hepatitis B infection led to a 10,000-fold lower 
multiplicity of infection, compared to non-perfused 
culture [70]. A bioreactor-engineered model of 
neuronal tissue infected by the varicella-zoster virus 
maintained persistent viral infection for 90 days, 
which is not possible with non-perfused culture 
[68-69]. 
4) Perfusion increases the level and stability of cell 
marker expression 
In a 3D bioreactor-engineered respiratory 
epithelium infected with SARS-CoV, the antibody 
response to SARS-CoV-specific spike and 
nucleocapsid glycoproteins was two-fold, compared 
to non-perfused culture [67-68]. A bioreactor- 
engineered liver model of hepatitis B infection 
maintained stable expression levels of receptors of 
innate immune cells and downstream effectors, 
compared to non-perfused cultures [70]. 
The evidence above therefore shows that 
perfused models enable infection studies to be 
extended even up to several months, on stable cell 
cultures of highly differentiated cells, with a higher 
infection efficiency and lower multiplicity of infection, 
compared to non-perfused models. This makes it 
potentially feasible to extend the study of the life cycle 
and genetic stability of new viruses such as SARS- 
CoV-2 to in vitro systems, despite being derived from 
minimal doses from patients, and to test sequential 
antiviral drug treatments [70]. Most importantly, 
perfused cell models make it feasible to reproduce 
dynamic interactions between tissue-resident cells 
and circulating cells, including the response to a 
pathogen of innate and adaptive immune cells and 
thus, to extend the testing of vaccines to in vitro 
models. 
A first step forward in this regard is a recent 
microfluidic-based model of a lymph node [72]. Here, 
the stroma was modeled with adherent murine tumor 
dendritic cells, and CD4+ and CD8+ T lymphocytes 
were put in suspension in the culture medium and 
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recirculated interstitially within the engineered organ. 
This system selectively promoted the adhesion of 
antigen-specific T cells through affinity isolation by 
serial cell contacts, with fluid-induced shear stresses 
maintained in the range 0.1–1 dyn/cm2. In contrast to 
non-perfused cultures, this model was able to 
compare in parallel and in real time, the effect on T 
cell adhesion to dendritic cells of different treatments, 
inhibitors, activators and immunogens. 
With regard to vaccine testing, bioreactors that 
host cm-sized 3D scaffolds such as the rotating wall 
vessel are able to provide tens of millions cells for 
confirmation assays such as PCR or FACS, as required 
by regulatory agencies. Their technological limitation, 
however, is that they are too thick to be accessed 
thoroughly for real time optical inspection of cell 
interactions [54,73]. Microfluidic bioreactors, instead, 
are 2D and have micron-sized channels that are also 
fully inspectable in real time [74-75]. However, they 
can host only a few thousand cells which are difficult 
to harvest and in any case would not be sufficient for 
robust confirmation assays [76]. 
To overcome these limitations, our group 
developed a millifluidic optically-accessible 
bioreactor (MOAB), which is a compromise between 
the two categories mentioned above. The MOAB 
(Figure 3) is a chambered microscope slide allowing 
the culture of fully 3D cell models with dimensions of 
up to a few millimeters, containing several million 
cells, under interstitial perfusion of the culture 
medium, with the infusion of cells in suspension and 
the therapeutic agents to be tested. The culture 
chambers are only 400 microns thick and enable 
full-thickness high-resolution fluorescence 
diagnostics, both in real time and post-cultivation 
[77-81]. In in vitro tests, the MOAB led to a comparable 
cell response to biodrugs to the one seen in 
experimental animals, in specific fields characterized 
by slowly-developing diseases and slowly-developing 
healing induced by the therapeutic agent: stem cell 
therapy for neurodegeneration [82], gene therapy for 
muscular dystrophy [83], and chemotherapy for bone 
metastases [84]. 
By adding lymphocytes in suspension in the 
perfused medium (Figure 3), the MOAB easily 
extended to 3D a microfluidic model of lymphocytes 
instruction within a lymph node [72]. Millifluidic 
bioreactors in fact have a high potential to speed up 
the discovery and testing of drugs and new vaccines 
for SARS-CoV-2 and are not limited to the interactions 
with the immune system. For example, they can 
successfully maintain human primary neurons 
infected by a virus in long-term culture for up to 180 
days, compared to the limit of a few days in 
non-perfused culture [68-69]. Millifluidic bioreactors 
can even be hydraulically connected in multiple units, 
to reproduce transport of neurotoxic agents through 
multiple body barriers pertaining to distant body 
compartments, for example from the gut endothelial 
barrier to the blood-brain-barrier [85]. This method 
can be exploited to assess neurotoxicity, which is a 
primary concern for new antiviral drugs and vaccines 
for SARS-CoV-2. 
In addition, the SARS-CoV-2 virus itself could 
hold a neurotropic potential. New observations on the 
loss of smell and taste by patients later manifesting 
symptoms of COVID-19, together with evidence 
showing that coronaviruses such as SARS-CoV and 
MERS-CoV could target the central nervous system, 
open up a new window in this regard [86]. In fact, a 
long-term bioreactor co-culture of olfactory neurons 
and ensheathing glial cells in 3D, could not only 
confirm the expression of ACE2 in human olfactory 
neurons, thus their role as a potential entry site for the 
SARS-CoV-2 virus, but also could help to clarify the 
potential mechanism of virus propagation to the brain 
through neural cell populations, i.e. from the olfactory 
neurons to their ensheathing glial cells. Such a model 
could verify whether, in SARS-CoV-2 infection, the 
defense mechanism provided by olfactory 
ensheathing cells is present, and whether it is 
maintained during aging. Such an experiment could 
add crucial insights into unveiling the possible 
contribution of neurological tissue damage to the 
morbidity and mortality caused by COVID-19 [11], 
also suggesting new prevention measures, such as the 
vaporization of nasal disinfectants in the elderly 
population. 
Intravital imaging models in vivo for drug 
testing 
Immunization addresses the response of innate 
and adaptive immune cells to a pathogen, which is a 
very complex and slowly-developing phenomenon 
commonly studied in vivo. In advanced study models 
of the immune response to influenza viruses, the 
experimental animals were directly accessed with a 
microscope for intravital real time optical inspection 
of organs including the nasal cavity [87], trachea [88], 
and lungs [89-91]. 
Table 6 shows some examples of the intravital 
imaging models published in the field of 
immunization. The most elegant procedures generally 
consist in surgically creating a direct percutaneous 
access for the microscope objective, often using 
metallic holders, in transgenic mice with fluorescent 
CD4+ T cells and/or T cell receptors, and in 
visualizing their interactions with inoculated 
recombinant vaccine viruses also expressing 
fluorescent proteins [87-90,92-96]. Compared to 
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conventional post-mortem histopathology, several 
key advantages of intravital imaging techniques can 
be highlighted in speeding-up the preclinical 
evaluation of vaccines and novel antiviral therapies. 
1) Dynamics of infection progression and the effects of 
vaccines and drugs 
These can be quantified in real time with a 
resolution at the cellular scale. For example, intravital 
imaging studies in lungs quantified in time the 
recruitment of CD4+ T cells from blood vessels in 
response to the influenza A virus [89-90] and, most 
recently, the recruitment of neutrophils in response to 
the PR8-H1N1 and H5N5 influenza viruses [91]. 
Multiphoton intravital microscopy in abdominal 
lymph nodes was used to quantify a partial reduction 
in the motility of HIV-infected T cells as well as their 
tethering to and fusion with CD4+ immune cells 
[92-93]. Intravital imaging within vessels of colon 
adenocarcinoma tumors was used to quantify the 
timely evolution of several oncolytic viruses binding 
to intravascular leukocytes and endothelial cells 
[94-95]. 
2) Sensitivity and robustness of intravital imaging to 
assess immunization 
These parameters are greater than in in vitro 
assays. For example, in an immunization study, using 
a glycoprotein of the respiratory syncytial virus, 
associated with an antiviral treatment with the 
specific monoclonal antibody, live imaging was used 
to visualize and capture virus-infected cells in the 
nasal cavity and in the lungs of experimental mice 
with a higher sensitivity compared to the in vitro 
plaque assay [87]. Intravital imaging of live mice was 
sufficiently sensitive to quantify vaccinia viruses in 
ear blood vessels and labial mucosa [96], and single 
oncolytic virus particles interacting with individual 
leukocytes and endothelial cells within blood, tumors, 
and visceral organs [94-95]. 
Intravital imaging is thus emerging as a key tool 
to observe the spatial-temporal dynamics of very 
complex phenomena, even as complex as embryonic 
development, at a cellular resolution [97]. 
In the field of immunology, however, intravital 
imaging models have significant limitations. 
Temporary “suction” window chambers are highly 
invasive and always require animal euthanization at 
the end of each observation, preventing repeated 
observations at subsequent time points. In contrast, 
implantable windows allow for long-term repeated 
observations in the same animal. However, they are 
currently too invasive and affected by chronic 
inflammation at the surgical site, thus interfering with 
the desired measurements [88]. In addition, implanted 
imaging windows in general do not retain lymphatic 
circulation, thus preventing the recruitment of cells 
from the bone marrow or lymphatic system [89-90]. 
 
Table 6. In vivo models of viral infection based on intravital imaging 
Refs. Pathogen Function monitored Imaged Cell type/s Imaging window configuration Imaged Organ/District 
[91] Influenza viruses: 
PR8-H1N1, 
PR8-H5N1. 
Correlated pathological changes in the lungs 
of live animals at the cellular level (labeled 
immune-related cells) in response to 
influenza viruses. 
Madin–Darby canine 
kidney cells for virus 
propagation. 
Mice immune-related 
cells. 
Thoracotomy incision and left 
lung immobilization by vacuum. 
Left lung. 
[89-90] Influenza A virus 
(IAV). 
CD4+ T cells responding to IAV in the mice 
lung. 
Mouse transgenic 
CD4+ T cells. 
 
 
Thoracotomy incision and left 
lung immobilization by vacuum. 
Lung. 
[88] Influenza virus (PR8- 
H1N1). 
Neutrophil and dendritic cell interactions 
with influenza virus at the tracheal site. 
Neutrophils, dendritic 
cells. 
Tracheal exposure by removing 
the tissue and muscles. 
Trachea. 
[87] Respiratory 
Syncytial Virus 
(RSV) A2-Line19F.  
Kinetics of RSV infection in the nasal cavity 
and in the lungs of live BALB/c mice infected 
with a recombinant virus strain expressing 
firefly luciferase gene (RSV A2-Line19FFL). 
Immunization versus therapy by either 
vaccination with 5 𝜇𝜇g of DS-Cav1, a 
glycoprotein of the syncytial virus, or 
treatment with the monoclonal antibody 
Palivizumab. 
Virus expansion: A549, 
Hep-2. 
Whole body live imaging 
without specific localization of 
window. 
Whole body imaging 
detected strong 
bioluminescence 
signal in the nasal 
cavity and in the lungs. 
[92-93] HIV. HIV infection on T cell migration. HEK293T cell line 
(virus expansion), 
Human CD4+ central 
memory-like T cells. 
Abdominal exposure with 
permanent imaging device 
implanted. 
Popliteal lymph nodes 
(popLN). 
[94-95] Oncolytic Viruses 
(OV): vesicular 
stomatitis virus 
(VSV); maraba virus; 
reovirus. 
Interaction between OV and tumor in vivo. Virus expansion: Vero 
cells (Vesicular Virus); 
L929 (Reovirus). 
Tumor model: CT-26 
(murine colon 
adenocarcinoma). 
Dorsal/Abdominal exposure 
with no permanent imaging 
device implanted. 
Skin/endothelium. 
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Refs. Pathogen Function monitored Imaged Cell type/s Imaging window configuration Imaged Organ/District 
[96] Vaccinia virus 
(VACV). 
VACV infection of mice to study both the 
movement of infected cells and the response 
of innate and adaptive immune cells into skin 
and mucosa. 
Infected cells. Craniocaudal exposure: (1) Ear 
sealing with no external device 
or wound generation;  
(2) Lower labial mucosa exposed 
into a steel stage. 
(1) Ear blood vessels; (2) 
Labial mucosa. 
 
 
 
Figure 4. Miniaturized “Microatlas” imaging window for intravital microscopy. A frontier imaging window device used for mini invasive quantitative 
analyses of living organisms, without any persistent percutaneous access. The device incorporates micro-scaffolds micro-fabricated by two-photon 
polymerization. The device was developed for animal examinations with optical fluorescence microscopy techniques. A) The device was validated by studying 
the reaction of the foreign body of the implant, and the animal model used was the chicken embryo. The widely employed Chorioallantoic Membrane (CAM) assay was used to 
quantify and characterize the amount of reaction occurring inside the imaging device. Here an image of a living embryo on the 8th day of incubation: the device was implanted in 
the membrane (red dot-circle). B) Rendering representation of the implant set-up. The device lies on the membrane. No conditioning factors were administered. C) Zoomed 
rendered detail of the tissue infiltration inside the micro-scaffold device. The mechanical conditioning, alone, guides the tissue regeneration in situ, allowing a fast 
neovascularization in the structure porosity. D) Example of possible fluorescence acquisitions that quantify the foreign reaction. In the upper part is the window imaging, with 
respect to the control, which is reported into the lower part. Second Harmonic Generation (left), tissue autofluorescence (middle) and nuclear dyes (right) were used for the 
examination in real-time. E) Graphical quantitative representation of the reaction occurring in terms of collagen fibers orientation, differential neo-vascularization rate and 
differential cellular density in subsequent incremental time-points. Scale bars: 50 µm. 
 
To overcome these limitations, we developed an 
implantable miniaturized intravital imaging device 
called Microatlas (Figure 4). This minimally invasive 
device, which is 5 mm in diameter and 1 mm in 
thickness, is implantable in chicken embryos or 
subcutaneously in mice to quantify in vivo aspects of 
the immune response to biomaterials and drugs [98]. 
Microatlas integrates a micro-fabricated fluorescent 
3D scaffold that guides and hosts the intravital 
regeneration of vascularized tissue. In addition, this 
scaffold enables the repositioning of the observation 
field of view of a two-photon microscope, which is 
necessary for repeated and quantitative intravital 
measurements of immune cell recruitment, neo- 
angiogenesis and fibrotic reaction, on the same animal 
at different time-points. The fluorescent grid is 
currently designed to provide beacons to correct 
aberrations derived from deep optical sectioning of 
the 3D micro-scaffold repopulated by cells during ex 
ovo experiments. 
Expression of the human ACE2 receptor can be 
engineered in transgenic mice. In contrast with 
histopathology techniques, imaging through a 
miniaturized intravital window can be used at 
Theranostics 2020, Vol. 10, Issue 15 
 
 
http://www.thno.org 
7048 
incremental time points within the same mouse, in 
vital conditions to study the localization and 
distribution, pharmacokinetics, and the 
pharmacodynamics of antiviral therapies and 
vaccines. While seeking solutions for COVID-19, it 
could significantly speed-up the preclinical testing of 
experimental antiviral drugs and vaccines, while 
eliminating the need for animal sacrifice at the various 
time points, thus reducing by up to 90% the number 
of animals required by the regulation for ex vivo 
assessments. 
Intravital imaging could be very effective in this 
model also to test therapeutic agents based on an 
engineered messenger RNA (mRNA) that directs cells 
to make a protein which could work as a drug or 
vaccine for SARS-CoV-2. Human safety trials have 
already begun for mRNA-based vaccines against two 
flu strains and the zika virus. In each case, the mRNA 
encodes for viral proteins that infected cells would 
physiologically present to activate the immune 
system against infections. To succeed, the engineered 
mRNA must hide from dendritic cells, enter the cells, 
avoid degradation, and be translated efficiently. The 
efficiency off all these stages could be monitored and 
measured by the intravital imaging of fluorescently- 
labeled mRNA. 
Conclusions 
In this review, we have discussed various 
cutting-edge bioengineering tools already available in 
the fields of virology and pharmacology, which are 
based on i) 3D co-cultures that are highly predictive of 
in vivo mechanisms and, ii) high-resolution intravital 
microscopy. We have also discussed the potential 
strategies aimed at repurposing these tools in order to 
significantly accelerate the development of 
therapeutics and vaccines against COVID-19. 
Although several academic institutions have 
already adopted these improved tools for research 
into basic immune biology and drug discovery, 
pharmaceutical companies still use conventional cell 
lines and standardized animal models for 
confirmatory studies, as requested by the standards 
for the passage of new drugs through the preclinical 
steps of regulatory approval, but despite the limited 
predictive capability of these models. 
The particular urgency to find clinical solutions 
for the SARS-CoV-2 pandemic makes it even more 
evident that an adequate validation of these new tools 
could lead to an update of the current preclinical 
testing standards, with the new ones based on the 
concepts of 3D culture, perfused culture and intravital 
imaging presented here. 
In virology and vaccinology, as well as in many 
other pharmaceutical sectors, the new standards 
suggested in our review would improve the efficiency 
and effectiveness of the whole drug development 
process, with the added benefit of drastically 
reducing, refining and widely replacing animal 
testing. 
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